ArticleBMC endocrine disorders2026
Association between thyroid hormone index TFQIFT3 and diabetic peripheral neuropathy: a retrospective cross-sectional analysis in euthyroid individuals with type 2 diabetes.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe relationship between thyroid hormone sensitivity and diabetic peripheral neuropathy (DPN) remains unclear. The Thyroid Feedback Quantile-based Index using FT3 (TFQIFT3) is considered a sensitive marker of peripheral thyroid hormone activity. This study aimed to investigate the association between TFQIFT3 and DPN in euthyroid individuals with type 2 diabetes mellitus (T2DM).
methodsThis retrospective cross-sectional study analyzed euthyroid adults with T2DM hospitalized at the Endocrinology and Metabolism Department, Qingpu Branch of Zhongshan Hospital, Fudan University, from January 2019 to July 2023. Patients were categorized into quartiles based on TFQIFT3 levels. The primary outcome was DPN diagnosis, assessed via clinical symptoms and electromyography. Multivariable logistic regression was used to evaluate the association between TFQIFT3 and DPN, adjusting for relevant confounders.
resultsA total of 1,040 euthyroid adults with T2DM were included, with a mean age of 57.4 ± 13.3 years, and 62.8% were male. The prevalence of DPN was 42.3% in Q1, 40.8% in Q2, 39.2% in Q3, and 28.8% in Q4 (P = 0.006). After adjusting for all confounders, TFQIFT3 was significantly associated with DPN (OR = 0.68, 95% CI: 0.48–0.95, P = 0.023). Stratified analyses indicated a more pronounced TFQIFT3-DPN association in non-smokers, individuals with BMI ≤ 24 kg/m², metformin users, and those with a diabetes duration > 60 months.
conclusionElevated TFQIFT3 levels were associated with a reduced risk of DPN. While TFQIFT3 has potential for DPN risk stratification, further prospective studies are needed to confirm these findings and explore the underlying mechanisms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.